Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer.

被引：0
|
作者：
Schmitt, C
Levy-Piedbois, C
Frappé, M
Durand-Zaleski, I
Gruia, G
Alakl, M
Rougier, P
机构：
[1] Hop Ambroise Pare, Boulogne, France
[2] Aventis Pharma, Antony, France
[3] Hop Henri Mondor, Dept Publ Hlth, F-94010 Creteil, France
[4] Inst Gustave Roussy, Dept Publ Hlth & Informat, Villejuif, France
[5] Phoenix Int, MDS Pharma Serv, Sevres, France
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
202P
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [31] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
  • [32] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    Advances in Therapy, 2022, 39 : 2614 - 2629
  • [33] Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis
    Liang Xiao-bo
    Hou Sheng-huai
    Li Yao-ping
    Wang Li-chun
    Zhang Xin
    Yang Jun
    CHINESE MEDICAL JOURNAL, 2010, 123 (22) : 3314 - 3318
  • [34] Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer
    Ji, SH
    Park, YS
    Lee, J
    Lim, DH
    Park, BB
    Park, KW
    Kang, JH
    Lee, SH
    Park, JO
    Kim, K
    Kim, WS
    Jung, CW
    Im, YH
    Kang, WK
    Park, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) : 214 - 217
  • [35] Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma
    Hillner, BE
    Schrag, D
    Sargent, DJ
    Fuchs, CS
    Goldberg, RM
    CANCER, 2005, 104 (09) : 1871 - 1884
  • [36] Adding weekly irinotecan to high-dose fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer - a phase II study
    Hofheinz, R
    Hartung, G
    Samel, S
    Emig, M
    Pilz, L
    Willeke, F
    Hochhaus, A
    Hehlmann, R
    Queisser, W
    ANTI-CANCER DRUGS, 2002, 13 (10) : 999 - 1004
  • [37] Bolus 5-fluorouracil plus leucovorin (FU-LV) in first-line treatment of advanced colorectal cancer.
    López, A
    Sánchez, J
    Gómez-Aldaraví, JL
    Fernández-Aramburo, A
    Yustos, A
    Romero, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S75 - S75
  • [38] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
    Simons, WR
    Jones, D
    Buzdar, A
    CLINICAL THERAPEUTICS, 2003, 25 (11) : 2972 - 2987
  • [39] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [40] Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
    Georgieva, Mina
    da Silveira Nogueira Lima, Joao P.
    Aguiar, Pedro
    Lopes, Gilberto de Lima, Jr.
    Haaland, Benjamin
    LUNG CANCER, 2018, 124 : 248 - 254
12345